Loading…
Marketing Rx&D: The CMA president responds
The focus of Yeo's commentary relates to the pharmaceutical industry's introduction of a provision in the revised Rx&D code that allows Rx&D companies to consider "requests from individual physicians, specialty societies, and/or academic institutions for financial assistance t...
Saved in:
Published in: | Canadian Medical Association journal (CMAJ) 2003-05, Vol.168 (10), p.1274-1274 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The focus of Yeo's commentary relates to the pharmaceutical industry's introduction of a provision in the revised Rx&D code that allows Rx&D companies to consider "requests from individual physicians, specialty societies, and/or academic institutions for financial assistance to participate in CHE [continuing health education] events held outside Canada."2 As I noted in my Mar. 18 letter to the membership,4 this does not conform to the CMA guidelines. Item 24 of those guidelines limits the payment of honoraria and travel expenses to faculty. The issue of faculty development is not currently addressed in the CMA guidelines, but will be considered for future inclusion. We understand the Rx&D code to be a work in progress and look forward to further discussions to bring the Rx&D code fully in line with the CMA's guidelines. |
---|---|
ISSN: | 0820-3946 1488-2329 |